Gilead makes another ADC move, inking up to $415M pact with Tubulis

Kyle LaHucik

Senior Reporter

Gilead is enlisting a new partner in the bustling field of antibody-drug conjugates, a type of chemotherapy that it’s struggled to capitalize on since buying …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead makes another ADC move, inking up to $415M pact with Tubulis

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Judge halts some NIH cuts after 22 states sue

Merck KGaA confirms interest in acquiring cancer biotech SpringWorks

Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharma

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Boehringer Ingelheim touts success in second Phase 3 lung fibrosis trial

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Gilead makes another ADC move, inking up to $415M pact with Tubulis